EP0805687A4 - Alpha-f toproteine humaine recombinante et ses utilisations - Google Patents

Alpha-f toproteine humaine recombinante et ses utilisations

Info

Publication number
EP0805687A4
EP0805687A4 EP96905219A EP96905219A EP0805687A4 EP 0805687 A4 EP0805687 A4 EP 0805687A4 EP 96905219 A EP96905219 A EP 96905219A EP 96905219 A EP96905219 A EP 96905219A EP 0805687 A4 EP0805687 A4 EP 0805687A4
Authority
EP
European Patent Office
Prior art keywords
fetoprotein
recombinant human
human alpha
mammal
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96905219A
Other languages
German (de)
English (en)
Other versions
EP0805687A1 (fr
Inventor
Robert A Murgita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Martinex R&D Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/377,309 external-priority patent/US5965528A/en
Priority claimed from US08/505,012 external-priority patent/US6331611B1/en
Application filed by Individual filed Critical Individual
Publication of EP0805687A1 publication Critical patent/EP0805687A1/fr
Publication of EP0805687A4 publication Critical patent/EP0805687A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

L'invention décrit en général des procédés empêchant la prolifération cellulaire immune autoréactive chez un mammifère, comprenant l'administration au mammifère d'une quantité thérapeutique moins efficace d'une alpha-f÷toprotéine humaine recombinante ou un fragment ou un analogue d'antiprolifération de cellules immunes; des procédés d'inhibition d'un néoplasme chez un mammifère, comprenant l'administration au mammifère d'une quantité thérapeutique moins efficace d'une alpha-f÷toprotéine humaine recombinante ou un fragment ou analogue anti-néoplasme de celle-ci; et des procédés de culture de cellules impliquant l'utilisation d'un milieu contenant une alpha-f÷toprotéine humaine recombinante ou un fragment ou analogue de celle-ci.
EP96905219A 1995-01-24 1996-01-24 Alpha-f toproteine humaine recombinante et ses utilisations Ceased EP0805687A4 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US505012 1983-06-16
US37731695A 1995-01-24 1995-01-24
US37731795A 1995-01-24 1995-01-24
US37731195A 1995-01-24 1995-01-24
US377309 1995-01-24
US08/377,309 US5965528A (en) 1991-09-27 1995-01-24 Recombinant human alph-fetoprotein as an immunosuppressive agent
US377311 1995-01-24
US377317 1995-01-24
US377316 1995-01-24
US08/505,012 US6331611B1 (en) 1991-09-27 1995-07-21 Expression and purification of cloned human alpha-fetoprotein
PCT/US1996/000996 WO1996022787A1 (fr) 1995-01-24 1996-01-24 Alpha-f×toproteine humaine recombinante et ses utilisations

Publications (2)

Publication Number Publication Date
EP0805687A1 EP0805687A1 (fr) 1997-11-12
EP0805687A4 true EP0805687A4 (fr) 2000-05-31

Family

ID=27541364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96905219A Ceased EP0805687A4 (fr) 1995-01-24 1996-01-24 Alpha-f toproteine humaine recombinante et ses utilisations

Country Status (6)

Country Link
EP (1) EP0805687A4 (fr)
JP (2) JPH10513347A (fr)
CN (1) CN1150030C (fr)
AU (1) AU700975B2 (fr)
CA (1) CA2211324C (fr)
WO (1) WO1996022787A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6288034B1 (en) 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US7098306B2 (en) 1997-02-13 2006-08-29 The Regents Of The University Of California Method and compositions for treating hepatocellular cancer
WO2001058922A2 (fr) * 2000-02-10 2001-08-16 The Regents Of The University Of California Methodes et compositions destinees au traitement du cancer hepatocellulaire
JP3816959B2 (ja) * 1997-02-13 2006-08-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肝細胞癌の予防および処置
US7208576B2 (en) 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
CA2354638C (fr) * 1999-01-06 2013-03-19 Atlantic Biopharmaceuticals, Inc. Expression d'alpha-foetoproteines humaines secretees chez des animaux transgeniques
US7022892B1 (en) 1999-07-12 2006-04-04 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
AU5798600A (en) * 1999-07-12 2001-01-30 Universite Libre De Bruxelles Non-human genetically modified mammal lacking the alpha-fetoprotein
RU2154468C1 (ru) * 1999-11-09 2000-08-20 Родионов Сергей Юрьевич Способ получения таблеток альфа-фетопротеина
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
US7074561B2 (en) * 2002-10-22 2006-07-11 Biomerieux, Inc. Isothermal amplification based assay for the detection and quantitation of alpha-fetoprotein mRNA
US20060111289A1 (en) * 2004-09-09 2006-05-25 Serometrix, Llc, Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides
US8932829B2 (en) 2005-07-07 2015-01-13 Elena Dudich Recombinant alpha-fetoprotein and compositions thereof
GB0617564D0 (en) * 2006-09-06 2006-10-18 Ucl Business Plc Peptides and methods
JP2010513518A (ja) * 2006-12-19 2010-04-30 メリマック ファーマシューティカルズ インコーポレーティッド 多発性硬化症治療ためのα‐フェトプロテインおよび免疫調節作用物質の同時投与方法
WO2008113970A2 (fr) * 2007-03-16 2008-09-25 Ucl Business Plc Peptides
CN105732795A (zh) * 2016-03-21 2016-07-06 海南医学院 一种获得人类甲胎蛋白的方法
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001812A1 (fr) * 1977-10-27 1979-05-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation et application de la alpha-1-fétoprotéine
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
EP0353814A2 (fr) * 1988-07-29 1990-02-07 SCLAVO S.p.A. Peptides synthétiques à activité immunologique, favorisant la production d'anticorps avec haute spécificité contre alpha-fétoprotéine, leur emploi dans le domaine des diagnostiques
WO1993005774A1 (fr) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0356399A3 (fr) * 1988-08-26 1991-03-20 Sandoz Ag Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
CA2120131A1 (fr) * 1991-09-27 1994-05-11 Robert A. Murgita Expression et purification d'alphafoetoproteine humaine clonee
US5907649A (en) * 1994-09-26 1999-05-25 Siemens Aktiengesellschaft Coupling arrangement for optically coupling together an OEIC module and optical fibers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001812A1 (fr) * 1977-10-27 1979-05-16 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation et application de la alpha-1-fétoprotéine
JPH025866A (ja) * 1988-06-27 1990-01-10 Kansai Shin Gijutsu Kenkyusho:Kk ヒトアルファフェトプロテインドメインｉ遺伝子、対応プラスミド組換体、対応形質転換体、該ドメインｉの製造法及び製造された該ドメインｉ
EP0353814A2 (fr) * 1988-07-29 1990-02-07 SCLAVO S.p.A. Peptides synthétiques à activité immunologique, favorisant la production d'anticorps avec haute spécificité contre alpha-fétoprotéine, leur emploi dans le domaine des diagnostiques
US5206153A (en) * 1990-06-27 1993-04-27 Snow Brand Milk Products Co., Ltd. Method of producing human α-fetoprotein and product produced thereby
WO1993005774A1 (fr) * 1991-09-25 1993-04-01 Wisconsin Alumni Research Foundation Complexes d'antibiotiques d'anthracycline et d'acides gras polyinsatures dans des emulsions de lipides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOISMENU R. ET AL.: "Expression of domains of mouse alpha-fetoprotein in Escherichia coli.", LIFE SCIENCES, vol. 43, no. 8, 1988, pages 673 - 681, XP002118047 *
MURGITA R. ET AL.: "Adult murine T cells activated in vitro by alpha-fetoprotein and naturally occurring T cells in newborn mice: identity in function and cell surface differentiation antigens", PROC. NATL. ACAD. SCI. USA, vol. 75, no. 6, 1978, pages 2897 - 2901, XP002118046 *
See also references of WO9622787A1 *

Also Published As

Publication number Publication date
AU4903596A (en) 1996-08-14
EP0805687A1 (fr) 1997-11-12
JPH10513347A (ja) 1998-12-22
HK1010153A1 (en) 1999-06-17
CA2211324C (fr) 2012-07-10
CN1150030C (zh) 2004-05-19
CA2211324A1 (fr) 1996-08-01
CN1179106A (zh) 1998-04-15
JP2008073041A (ja) 2008-04-03
AU700975B2 (en) 1999-01-14
WO1996022787A1 (fr) 1996-08-01

Similar Documents

Publication Publication Date Title
EP0805687A4 (fr) Alpha-f toproteine humaine recombinante et ses utilisations
RO115700B1 (ro) Metodă de tratament cu interferon
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
NZ511020A (en) Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
AU2993297A (en) Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
IL111681A0 (en) Recombinant viruses and their use in gene therapy
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
GR3036691T3 (en) Dna sequences related to isolated fragile x syndrome
AU1209995A (en) Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases
IL111682A0 (en) Recombinant viruses and their use in gene therapy
AU3878895A (en) Use of nitric oxide donors in medicine
EP0656069A4 (fr) Inhibiteurs de la proliferation cellulaire, preparation et utilisation.
AU628288B2 (en) Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
AU1636492A (en) Peptides having thrombospondin-like activity and their therapeutic use
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
DE3279834D1 (en) 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
IL131478A0 (en) Methods for treatment of scar tissue
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
ES8104315A1 (es) Un procedimiento de obtencion de un extracto de las fraccio-nes polares de los helechos de la familia polypodiaceae.
IL112993A0 (en) Recombinant niruses, their preparation and their use in gene therapy
WO1995007708A3 (fr) Utilisation therapeutique d'un produit genique contre la predisposition au retinoblastome
MY131599A (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
AU7780791A (en) Neonatal human blood bank and hematopoietic or immune reconstitutions performed therewith
AU1592801A (en) Methods of treating inflammatory bowel disease using cholera toxin B subunit

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT CH DE FR GB IT LI NL SE

17P Request for examination filed

Effective date: 19970801

RIC1 Information provided on ipc code assigned before grant

Free format text: 6C 12N 15/12 A, 6C 12N 15/62 B, 6C 07K 14/47 B, 6A 61K 38/17 B, 6C 07K 14/00 B, 6C 12P 21/02 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000414

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT CH DE FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20020311

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MARTINEX R&D INC.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MURGITA, ROBERT, A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20040708